Video Library

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

For this series, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced bone marrow transplant specialist and is active in

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses gilotrif/afatanib in squamous non small cell lung cancer.

Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses biomarkers for immunotherapy and if there is anything better than PDL1.

Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.

Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.

Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of angiogenesis in previously treated non-small cell lung cancer.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for second-line treatment.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy combined.